The insulin dilemma in resource-limited countries. A way forward? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-09-12

AUTHORS

G. V. Gill, J. S. Yudkin, H. Keen, D. Beran

ABSTRACT

The International Insulin Foundation (IIF) has developed and validated a needs-assessment instrument called the Rapid Assessment Protocol for Insulin Access (RAPIA) which has been used in seven countries in four continents to analyse the constraints to delivering effective continuing care for people with diabetes. One major contributor to the difficulties in availability of insulin is a failure to use the least costly sources and types of insulin and other effective drugs for diabetes. The purchase of insulins can consume as much as 10% of government expenditure on drugs, this being highly sensitive to the selection of newer analogue insulins as first-choice options, which cost between three and 13 times more than biosynthetic human insulin. Insulin cartridges for use with injection pens further add to costs. Similar considerations apply to most of the newer treatments for people with type 2 diabetes, which may cost up to 40 times more than metformin and sulfonylureas, still considered first-line drugs by European and US guidelines. Both biosynthetic human insulin and the first-line oral hypoglycaemic drugs are available from generic manufacturers. With the present price differentials, there is thus a growing need for countries involved in tendering for sourcing insulin to be provided with the guarantees of Good Manufacturing Practice, quality and bioequivalence, which would come from a WHO Pre-Qualification Scheme as currently exists for a variety of drugs for chronic diseases, both communicable and non-communicable. The IIF has developed a position statement on the provision and choice of diabetes treatments in resource-limited settings which should be applicable wherever consideration of resources is a component of therapeutic decision making. More... »

PAGES

19-24

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-010-1897-3

DOI

http://dx.doi.org/10.1007/s00125-010-1897-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008734213

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20835860


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gill", 
        "givenName": "G. V.", 
        "id": "sg:person.016135270442.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016135270442.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yudkin", 
        "givenName": "J. S.", 
        "id": "sg:person.0605764443.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605764443.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keen", 
        "givenName": "H.", 
        "id": "sg:person.01042343611.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042343611.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beran", 
        "givenName": "D.", 
        "id": "sg:person.0740370146.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740370146.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00125-008-1167-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000833388", 
          "https://doi.org/10.1007/s00125-008-1167-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-006-0454-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049292683", 
          "https://doi.org/10.1007/s00125-006-0454-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-007-0763-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025404427", 
          "https://doi.org/10.1007/s00125-007-0763-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6963-6-17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048661550", 
          "https://doi.org/10.1186/1472-6963-6-17"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-09-12", 
    "datePublishedReg": "2010-09-12", 
    "description": "The International Insulin Foundation (IIF) has developed and validated a needs-assessment instrument called the Rapid Assessment Protocol for Insulin Access (RAPIA) which has been used in seven countries in four continents to analyse the constraints to delivering effective continuing care for people with diabetes. One major contributor to the difficulties in availability of insulin is a failure to use the least costly sources and types of insulin and other effective drugs for diabetes. The purchase of insulins can consume as much as 10% of government expenditure on drugs, this being highly sensitive to the selection of newer analogue insulins as first-choice options, which cost between three and 13 times more than biosynthetic human insulin. Insulin cartridges for use with injection pens further add to costs. Similar considerations apply to most of the newer treatments for people with type 2 diabetes, which may cost up to 40 times more than metformin and sulfonylureas, still considered first-line drugs by European and US guidelines. Both biosynthetic human insulin and the first-line oral hypoglycaemic drugs are available from generic manufacturers. With the present price differentials, there is thus a growing need for countries involved in tendering for sourcing insulin to be provided with the guarantees of Good Manufacturing Practice, quality and bioequivalence, which would come from a WHO Pre-Qualification Scheme as currently exists for a variety of drugs for chronic diseases, both communicable and non-communicable. The IIF has developed a position statement on the provision and choice of diabetes treatments in resource-limited settings which should be applicable wherever consideration of resources is a component of therapeutic decision making.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00125-010-1897-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "54"
      }
    ], 
    "keywords": [
      "biosynthetic human insulin", 
      "oral hypoglycaemic drugs", 
      "human insulin", 
      "first-line drugs", 
      "type 2 diabetes", 
      "type of insulin", 
      "resource-limited countries", 
      "first-choice option", 
      "availability of insulin", 
      "resource-limited settings", 
      "variety of drugs", 
      "hypoglycaemic drugs", 
      "analogue insulin", 
      "chronic diseases", 
      "therapeutic decisions", 
      "US guidelines", 
      "injection pen", 
      "needs assessment instrument", 
      "diabetes treatment", 
      "effective drugs", 
      "new treatments", 
      "insulin access", 
      "insulin", 
      "diabetes", 
      "position statement", 
      "drugs", 
      "assessment protocol", 
      "treatment", 
      "good manufacturing practices", 
      "major contributor", 
      "metformin", 
      "sulfonylureas", 
      "disease", 
      "care", 
      "bioequivalence", 
      "consideration of resources", 
      "generic manufacturers", 
      "guidelines", 
      "people", 
      "failure", 
      "options", 
      "manufacturing practices", 
      "setting", 
      "countries", 
      "protocol", 
      "costly sources", 
      "time", 
      "expenditure", 
      "contributor", 
      "pen", 
      "rapid assessment protocol", 
      "need", 
      "use", 
      "practice", 
      "access", 
      "difficulties", 
      "quality", 
      "consideration", 
      "provision", 
      "types", 
      "differential", 
      "dilemma", 
      "choice", 
      "instrument", 
      "variety", 
      "availability", 
      "Similar considerations", 
      "statements", 
      "decisions", 
      "components", 
      "selection", 
      "cost", 
      "manufacturers", 
      "source", 
      "purchase", 
      "resources", 
      "way", 
      "foundation", 
      "continent", 
      "price differentials", 
      "government expenditure", 
      "tendering", 
      "constraints", 
      "scheme", 
      "guarantees"
    ], 
    "name": "The insulin dilemma in resource-limited countries. A way forward?", 
    "pagination": "19-24", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008734213"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-010-1897-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20835860"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-010-1897-3", 
      "https://app.dimensions.ai/details/publication/pub.1008734213"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00125-010-1897-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-010-1897-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-010-1897-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-010-1897-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-010-1897-3'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      120 URIs      108 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-010-1897-3 schema:about N18e8b4ff3eab44c8a6067a24808ae8d8
2 N38cbfee834a54d50bbc7631a72ba5dbf
3 N53b456f4d34c4e91bfcca38f17515733
4 N7444f1eb48cc4588a69a3eb5695c4c98
5 N7c36ad8d81344b718f02a3549b0a383f
6 Na3a1d7c887cb470484fe353bfd0d87cd
7 anzsrc-for:11
8 anzsrc-for:1103
9 schema:author N1e42bb3ca1b34ab4bad5df4f4396a26e
10 schema:citation sg:pub.10.1007/s00125-006-0454-6
11 sg:pub.10.1007/s00125-007-0763-4
12 sg:pub.10.1007/s00125-008-1167-9
13 sg:pub.10.1186/1472-6963-6-17
14 schema:datePublished 2010-09-12
15 schema:datePublishedReg 2010-09-12
16 schema:description The International Insulin Foundation (IIF) has developed and validated a needs-assessment instrument called the Rapid Assessment Protocol for Insulin Access (RAPIA) which has been used in seven countries in four continents to analyse the constraints to delivering effective continuing care for people with diabetes. One major contributor to the difficulties in availability of insulin is a failure to use the least costly sources and types of insulin and other effective drugs for diabetes. The purchase of insulins can consume as much as 10% of government expenditure on drugs, this being highly sensitive to the selection of newer analogue insulins as first-choice options, which cost between three and 13 times more than biosynthetic human insulin. Insulin cartridges for use with injection pens further add to costs. Similar considerations apply to most of the newer treatments for people with type 2 diabetes, which may cost up to 40 times more than metformin and sulfonylureas, still considered first-line drugs by European and US guidelines. Both biosynthetic human insulin and the first-line oral hypoglycaemic drugs are available from generic manufacturers. With the present price differentials, there is thus a growing need for countries involved in tendering for sourcing insulin to be provided with the guarantees of Good Manufacturing Practice, quality and bioequivalence, which would come from a WHO Pre-Qualification Scheme as currently exists for a variety of drugs for chronic diseases, both communicable and non-communicable. The IIF has developed a position statement on the provision and choice of diabetes treatments in resource-limited settings which should be applicable wherever consideration of resources is a component of therapeutic decision making.
17 schema:genre article
18 schema:isAccessibleForFree true
19 schema:isPartOf Nb36387e3cd684beca3f64018ec1d33bc
20 Nc469fca2852f4550be9093e894bae390
21 sg:journal.1001482
22 schema:keywords Similar considerations
23 US guidelines
24 access
25 analogue insulin
26 assessment protocol
27 availability
28 availability of insulin
29 bioequivalence
30 biosynthetic human insulin
31 care
32 choice
33 chronic diseases
34 components
35 consideration
36 consideration of resources
37 constraints
38 continent
39 contributor
40 cost
41 costly sources
42 countries
43 decisions
44 diabetes
45 diabetes treatment
46 differential
47 difficulties
48 dilemma
49 disease
50 drugs
51 effective drugs
52 expenditure
53 failure
54 first-choice option
55 first-line drugs
56 foundation
57 generic manufacturers
58 good manufacturing practices
59 government expenditure
60 guarantees
61 guidelines
62 human insulin
63 hypoglycaemic drugs
64 injection pen
65 instrument
66 insulin
67 insulin access
68 major contributor
69 manufacturers
70 manufacturing practices
71 metformin
72 need
73 needs assessment instrument
74 new treatments
75 options
76 oral hypoglycaemic drugs
77 pen
78 people
79 position statement
80 practice
81 price differentials
82 protocol
83 provision
84 purchase
85 quality
86 rapid assessment protocol
87 resource-limited countries
88 resource-limited settings
89 resources
90 scheme
91 selection
92 setting
93 source
94 statements
95 sulfonylureas
96 tendering
97 therapeutic decisions
98 time
99 treatment
100 type 2 diabetes
101 type of insulin
102 types
103 use
104 variety
105 variety of drugs
106 way
107 schema:name The insulin dilemma in resource-limited countries. A way forward?
108 schema:pagination 19-24
109 schema:productId N0bc9c93dd03648d18eecb4a86191e7b8
110 N4c1a93d1b106433db897e2260aa47f7b
111 Ne3ef88d0c4c14164b45f7c7982fddba6
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008734213
113 https://doi.org/10.1007/s00125-010-1897-3
114 schema:sdDatePublished 2022-12-01T06:28
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher N3417b59e12ef4f0a9deaad2b18ab6ca4
117 schema:url https://doi.org/10.1007/s00125-010-1897-3
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N0bc9c93dd03648d18eecb4a86191e7b8 schema:name pubmed_id
122 schema:value 20835860
123 rdf:type schema:PropertyValue
124 N18e8b4ff3eab44c8a6067a24808ae8d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Hypoglycemic Agents
126 rdf:type schema:DefinedTerm
127 N1e42bb3ca1b34ab4bad5df4f4396a26e rdf:first sg:person.016135270442.94
128 rdf:rest N5b1a69445ffd4113a8f8b710d5e218a9
129 N224a47ef4ce44ac0b2ed1d9b76345fff rdf:first sg:person.0740370146.23
130 rdf:rest rdf:nil
131 N3417b59e12ef4f0a9deaad2b18ab6ca4 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 N38cbfee834a54d50bbc7631a72ba5dbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Insulin
135 rdf:type schema:DefinedTerm
136 N4c1a93d1b106433db897e2260aa47f7b schema:name dimensions_id
137 schema:value pub.1008734213
138 rdf:type schema:PropertyValue
139 N53b456f4d34c4e91bfcca38f17515733 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Cost-Benefit Analysis
141 rdf:type schema:DefinedTerm
142 N5b1a69445ffd4113a8f8b710d5e218a9 rdf:first sg:person.0605764443.79
143 rdf:rest N755c531e8a234f4194c4392516e8870a
144 N7444f1eb48cc4588a69a3eb5695c4c98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N755c531e8a234f4194c4392516e8870a rdf:first sg:person.01042343611.09
148 rdf:rest N224a47ef4ce44ac0b2ed1d9b76345fff
149 N7c36ad8d81344b718f02a3549b0a383f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Animals
151 rdf:type schema:DefinedTerm
152 Na3a1d7c887cb470484fe353bfd0d87cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Diabetes Mellitus
154 rdf:type schema:DefinedTerm
155 Nb36387e3cd684beca3f64018ec1d33bc schema:volumeNumber 54
156 rdf:type schema:PublicationVolume
157 Nc469fca2852f4550be9093e894bae390 schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 Ne3ef88d0c4c14164b45f7c7982fddba6 schema:name doi
160 schema:value 10.1007/s00125-010-1897-3
161 rdf:type schema:PropertyValue
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
166 schema:name Clinical Sciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1001482 schema:issn 0012-186X
169 1432-0428
170 schema:name Diabetologia
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.01042343611.09 schema:affiliation grid-institutes:grid.83440.3b
174 schema:familyName Keen
175 schema:givenName H.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042343611.09
177 rdf:type schema:Person
178 sg:person.016135270442.94 schema:affiliation grid-institutes:grid.83440.3b
179 schema:familyName Gill
180 schema:givenName G. V.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016135270442.94
182 rdf:type schema:Person
183 sg:person.0605764443.79 schema:affiliation grid-institutes:grid.83440.3b
184 schema:familyName Yudkin
185 schema:givenName J. S.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605764443.79
187 rdf:type schema:Person
188 sg:person.0740370146.23 schema:affiliation grid-institutes:grid.83440.3b
189 schema:familyName Beran
190 schema:givenName D.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740370146.23
192 rdf:type schema:Person
193 sg:pub.10.1007/s00125-006-0454-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049292683
194 https://doi.org/10.1007/s00125-006-0454-6
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s00125-007-0763-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025404427
197 https://doi.org/10.1007/s00125-007-0763-4
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00125-008-1167-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000833388
200 https://doi.org/10.1007/s00125-008-1167-9
201 rdf:type schema:CreativeWork
202 sg:pub.10.1186/1472-6963-6-17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048661550
203 https://doi.org/10.1186/1472-6963-6-17
204 rdf:type schema:CreativeWork
205 grid-institutes:grid.83440.3b schema:alternateName International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK
206 schema:name International Insulin Foundation, Centre for International Health and Development, Institute for Child Health, 30 Guilford Street, London, UK
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...